• Overall rates of any AE were low in the ZAVICEFTA (ceftazidime–avibactam) and comparator arms^1-4
• Rates of all other categories of AEs were low and balanced across treatment arms^1-4
• Most common (≥ 5%) AEs for ZAVICEFTA were positive direct Coombs test, nausea and diarrhoea^5*
• Nausea and diarrhoea were usually mild or moderate in intensity^1-5
• No requirement for routine monitoring and a low potential for drug–drug interactions⁵
• In four Phase III clinical trials, the adverse-event profile of ZAVICEFTA was similar to that seen with either best-available therapy, doripenem or meropenem.^1-4

Zavicefta® (avibactam sodium, ceftazidime pentahydrate)

Zavicefta® (avibactam sodium, ceftazidime pentahydrate) 2g/0.5g powder for concentrate for
solution for infusion)

Meronem® (meropenem trihydrate) 

Meronem® (Meropenem Trihydrate) Meronem I.V. 1g